141 related articles for article (PubMed ID: 2534648)
1. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.
Heald PW; Perez MI; Christensen I; Dobbs N; McKiernan G; Edelson R
Yale J Biol Med; 1989; 62(6):629-38. PubMed ID: 2534648
[TBL] [Abstract][Full Text] [Related]
2. Photopheresis for the treatment of cutaneous T-cell lymphoma.
Lim HW; Edelson RL
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1117-26. PubMed ID: 8522488
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
4. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides.
Child FJ; Mitchell TJ; Whittaker SJ; Scarisbrick JJ; Seed PT; Russell-Jones R
Clin Exp Dermatol; 2004 May; 29(3):231-6. PubMed ID: 15115499
[TBL] [Abstract][Full Text] [Related]
5. Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
Schreiner T; Gaczkowski A; Scharffetter-Kochanek K; Borberg H
Transfus Apher Sci; 2005 Apr; 32(2):197-203. PubMed ID: 15784454
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.
Edelson R; Berger C; Gasparro F; Jegasothy B; Heald P; Wintroub B; Vonderheid E; Knobler R; Wolff K; Plewig G
N Engl J Med; 1987 Feb; 316(6):297-303. PubMed ID: 3543674
[TBL] [Abstract][Full Text] [Related]
8. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides.
Wilson LD; Jones GW; Kim D; Rosenthal D; Christensen IR; Edelson RL; Heald PW; Kacinski BM
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):54-60. PubMed ID: 10863224
[TBL] [Abstract][Full Text] [Related]
9. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy.
Heald P; Rook A; Perez M; Wintroub B; Knobler R; Jegasothy B; Gasparro F; Berger C; Edelson R
J Am Acad Dermatol; 1992 Sep; 27(3):427-33. PubMed ID: 1401279
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal methoxsalen: new drug. Cutaneous T cell lymphoma: for rare patients, but better assessment needed.
Prescrire Int; 2009 Feb; 18(99):16. PubMed ID: 19388212
[No Abstract] [Full Text] [Related]
11. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.
Bisaccia E; Gonzalez J; Palangio M; Schwartz J; Klainer AS
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):263-71. PubMed ID: 10906649
[TBL] [Abstract][Full Text] [Related]
12. Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Balogh A; Merkel U; Looks A; Vollandt R; Wollina U
Exp Toxicol Pathol; 1998 Sep; 50(4-6):397-401. PubMed ID: 9784014
[TBL] [Abstract][Full Text] [Related]
13. Photopheresis--extracorporeal irradiation of 8-MOP containing blood--a new therapeutic modality.
Knobler RM
Blut; 1987 Apr; 54(4):247-50. PubMed ID: 3493819
[TBL] [Abstract][Full Text] [Related]
14. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
15. Photoaccentuated erythroderma associated with CD4+ T lymphocytopenia: successful treatment with 5-methoxypsoralen and UVA, interferon alfa-2b, and extracorporeal photopheresis.
Wolf P; Müllegger R; Cerroni L; Aigner R; Fueger G; Höfler G; Derbaschnig J; Kerl H
J Am Acad Dermatol; 1996 Aug; 35(2 Pt 2):291-4. PubMed ID: 8698908
[TBL] [Abstract][Full Text] [Related]
16. Photopheresis for the treatment of cutaneous T cell lymphoma.
Armus S; Keyes B; Cahill C; Berger C; Crater D; Scarborough D; Klainer A; Bisaccia E
J Am Acad Dermatol; 1990 Nov; 23(5 Pt 1):898-902. PubMed ID: 2147701
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cutaneous T cell lymphomas with PUVA.
Rabbiosi G; Carcaterra A; Bellosta M
Int J Tissue React; 1986; 8(2):141-3. PubMed ID: 3486168
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and therapy of cutaneous T-cell lymphomas].
Le T; Pierard GE; Pierard-Franchimont C; de la Brassinne M; Lapière CM
Dermatologica; 1984; 169(2):60-5. PubMed ID: 6332749
[TBL] [Abstract][Full Text] [Related]
20. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Bisaccia E; Vonderheid EC; Geskin L
Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
